Well-conducted controlled clinical trials have shown an approximately 50% reduction in the rate of spine, hip, and wrist fracture in patients with osteoporosis who are receiving a bisphosphonate. Several bisphosphonates are approved for the treatment of osteoporosis in men and in postmenopausal women, as well as in patients with glucocorticoid-induced osteoporosis. In postmenopausal women, bisphosphonates have been shown to increase spine and hip mineral density.
Certain monoclonal antibodies are approved for treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture who are either initiating or continuing systemic glucocorticoids at a daily dosage equivalent to ≥ 7.5 mg of prednisone and who are expected to remain on glucocorticoids for ≥ 6 months. Patients considered at high risk for fracture are those with a history of osteoporotic fracture, those with multiple risk factors for fracture, those who cannot tolerate other available osteoporosis therapy, or those in whom other available osteoporosis therapies have failed.
Recombinant human parathyroid hormones are approved for the treatment of patients with glucocorticoid-induced osteoporosis and for use in women with postmenopausal osteoporosis who are at high risk for fracture or who were unable to tolerate previous osteoporosis therapy or in whom osteoporosis treatment has failed to increase bone mass. Parathyroid hormones are also indicated in men with idiopathic or hypogonadal osteoporosis who are at high risk for fracture, who have been intolerant of previous osteoporosis therapy, or in whom previous osteoporosis therapy has failed.
Learn more about treatment options for osteoporosis.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Herbert S. Diamond. Fast Five Quiz: Osteoporosis Prevention and Treatment - Medscape - Dec 10, 2020.